Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Fertility problems may raise risk of cancer in women

New research shows that women who have fertility problems are 18 percent more likely to develop ovarian and endometrial or womb cancers in later life.

13 Mar 2019

Cancer patients with mental health history have greater risk of death

Cancer patients who have been hospitalized for mental health problems prior to their cancer diagnosis were 73% more likely to die from their cancer compared to those who had never had psychiatric help, according to new research published in the British Journal of Cancer.

7 Mar 2019

Vapers develop cancer-related gene deregulation as cigarette smokers

If you think vaping is benign, think again. A small USC study shows that e-cig users develop some of the same cancer-related molecular changes in oral tissue as cigarette smokers, adding to the growing concern that e-cigs aren't a harmless alternative to smoking.

15 Feb 2019

Recurring UTIs may mask symptoms of bladder or kidney cancer

Women with bladder or kidney cancer may lose out on a prompt diagnosis if they are already being regularly treated for recurring urinary tract infections (UTIs), according to new research presented at Cancer Research UK's Early Diagnosis Conference in Birmingham today (Wednesday).

13 Feb 2019

New diagnostic technique reveals key protein biomarker for bladder cancer

Label-free digital pathology using infrared imaging with subsequent proteomic analysis for bladder cancer has revealed the first protein biomarker for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose.

12 Feb 2019

Trojan Horse approach to cancer therapy shows promise

A new form of cancer fighting drug has been developed using the principles of the “Trojan Horse”.

11 Feb 2019

New cancer drug that acts as ‘Trojan horse’ shows promise in patients with various cancers

A brand new type of cancer drug that acts as a 'Trojan horse' to get inside tumor cells has shown promise in patients with six different cancer types.

11 Feb 2019

'Trojan horse' drug shows promise for untreatable cancers

A new cancer drug that uses a ‘Trojan horse’ approach to destroy cancer cells from within has shown promising results for patients with untreatable cancers.

8 Feb 2019

The Truth About E-cigarettes: Quit Smoking this World Cancer Day

We asked Dr. Lion Shahab, one of the UK's leading experts on e-cigarettes and smoking, to provide the truth about the safety of vaping and for his advice to people giving up cigarettes this World Cancer Day.

4 Feb 2019

Johns Hopkins Greenberg Bladder Cancer Institute awards research grants to study how bladder cancer affects women

The Johns Hopkins Greenberg Bladder Cancer Institute awarded research grants to four projects that focus on understanding how treatment of bladder cancer affects women, why the disease has a less favorable outcome for women than men, and how biology could play a role in offering new targets for cancer therapy.

1 Feb 2019

Researchers use gene-editing tool CRISPR/Cas9 to limit impact of parasitic diseases

For the first time, researchers at the George Washington University, together with colleagues at institutes in Thailand, Australia, the U.K. and the Netherlands, and more, have successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and for liver fluke infection, which can cause a diverse spectrum of human disease including bile duct cancer.

16 Jan 2019

Cigarette smoking linked with poor outcomes in bladder cancer patients

In a study of patients with muscle-invasive bladder cancer who had undergone radical cystectomy, cigarette smoking was linked with poor response to cisplatin-based chemotherapy.

9 Jan 2019

Northwestern Medicine receives $10 million gift to create new institute for urologic cancers

Northwestern Medicine received a $10 million gift to fund the creation of a new multidisciplinary institute dedicated to urologic cancers.

7 Jan 2019

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.

7 Jan 2019

Researchers shed new light on how to combat Shiga and ricin toxins

Min Dong, PhD, and his lab are world experts in toxins and how to combat them. They've figured out how Clostridium difficile's most potent toxin gets into cells and zeroed in on the first new botulinum toxin identified since 1969.

11 Dec 2018

Researchers aim to demystify bladder immunity

We know that the bladder is a poorly understood organ, critical for storing metabolic waste. What we don’t know is how this unique environment impacts bladder immunity to common diseases such as urinary tract infections and bladder cancer.

6 Dec 2018

Engineers develop non-invasive method for detecting bladder cancer

A research team led by Tufts University engineers has developed a non-invasive method for detecting bladder cancer that might make screening easier and more accurate than current invasive clinical tests involving visual inspection of bladder.

4 Dec 2018

New report highlights key focus areas to help cancer screening realize its full potential

Cancer screening has contributed substantially to reduced incidence, morbidity, and mortality, but issues like access and quality care and have kept screening from fulfilling its full potential, according to a new report.

19 Nov 2018

New physical activity guidelines released that urge people to "move more"

The American Department of Health and Human Services has released a set of guidelines this Monday (12th November 2018) regarding the amount of exercise individuals need in order to stay healthy. The guidance is aimed at the sedentary population warning them of the ill effects of not being physically active.

13 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018